文献速递中枢神经肿瘤放疗放疗物理与技术

0.35 T磁共振直线加速器上磁共振弛豫测量评估胶质母细胞瘤放疗反应

Magnetic Resonance Imaging Relaxometry for Glioblastoma Response Assessment During Radiation Therapy on a 0.35 T Magnetic Resonance Imaging Linear Accelerator.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-02-22

38例胶质母细胞瘤患者在0.35 T磁共振直线加速器上接受放疗,每隔一天采集T2、T2*和T1定量图像,通过参数反应图评估肿瘤体素变化。进展者在第2周和第6周T2值升高体素比例更高,T2*值在第1、2、3周和最后一周更高。Cox模型显示第4周T2值升高与总生存和无进展生存相关,第2、3周T2*值升高与无进展生存相关。

要点

  • 进展者第2周T2升高体素比例49% vs 40%(P=.008),第6周58% vs 43%(P=.012)。
  • 第2、3周T2*升高与无进展生存相关(HR 5.02和6.04)。
  • 第4周T2升高与总生存(HR 4.72)和无进展生存(HR 9.26)相关。

核心结论

  • 放疗期间T2和T2*值的定量变化,尤其在放疗第3至4周,与疾病进展和生存结局相关。
  • 早期识别疗效不佳者可能有助于治疗调整,从而改善胶质母细胞瘤治疗结局。

研究设计与样本

  • 研究纳入38例胶质母细胞瘤患者,在0.35 T磁共振直线加速器上接受放疗。
  • 每隔一天采集策略性获取梯度回波和T2多回波序列。
  • 通过参数反应图比较每个治疗分次与放疗前基线的肿瘤T2、T2*和T1值逐体素变化。
  • 统计分析采用Wilcoxon检验进行组间比较,采用Cox比例风险模型分析生存关联。

主要发现

  • 进展者第2周T2值升高体素比例49% vs 40%(P=.008),第6周58% vs 43%(P=.012)。
  • 进展者第1周T2*值升高体素比例47% vs 43%(P=.016),第2周48% vs 43%(P=.016),第3周50% vs 44%(P=.012),最后一周53% vs 43%(P=.021)。
  • 第4周T2值升高与总生存相关(HR 4.72,95%CI 1.24-12.9),与无进展生存相关(HR 9.26,95%CI 1.88-24.5)。
  • 第2周T2*值升高与无进展生存相关(HR 5.02,95%CI 1.44-17.6),第3周与无进展生存相关(HR 6.04,95%CI 1.59-22.9)。
  • 第3周T2*值升高与总生存相关(HR 3.09,95%CI 0.94-10.1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The integration of magnetic resonance imaging (MRI) and linear accelerator (MRI-Linac) enables daily imaging during radiation therapy (RT). This study implements MRI-Linac relaxometry to evaluate quantitative imaging changes in patients with glioblastoma during RT and identify associations with disease progression and survival outcomes. METHODS AND MATERIALS: Thirty-eight patients with glioblastoma were treated on a 0.35 T MRI-Linac with Strategically Acquired Gradient Echo and T2 multiecho acquisitions every other day. Per voxel changes in tumor T2, T2*, and T1 values were assessed by parametric response mapping comparing each treatment fraction with pre-RT baselines. Statistical analyses included the Wilcoxon test for group comparisons and Cox proportional hazards models for survival associations. RESULTS: Progressors had higher proportions of voxels with increased T2 values at week 2 (49% vs 40%, P = .008) and week 6 (58% vs 43%, P = .012) and higher T2* values at week 1 (47% vs 43%, P = .016), week 2 (48% vs 43%, P = .016), week 3 (50% vs 44%, P = .012), and the final week (53% vs 43%, P = .021). Cox modeling linked increased T2 values at week 4 with overall survival (hazard ratio [HR], 4.72; 95% CI, 1.24-12.9) and progression-free survival (HR, 9.26; 95% CI, 1.88-24.5). Increased T2* values at weeks 2 and 3 correlated with progression-free survival (HR, 5.02; 95% CI, 1.44-17.6; HR, 6.04; 95% CI, 1.59-22.9) and overall survival at week 3 (HR, 3.09; 95% CI, 0.94-10.1). CONCLUSIONS: Quantitative changes in T2 and T2* values during RT, particularly in weeks 3 to 4, were associated with progression and survival outcomes. Early detection of poor responders may enable therapy adaptation, improving glioblastoma treatment outcomes.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Lutsik N, Nejad-Davarani SP, Valderrama A, et al. Magnetic Resonance Imaging Relaxometry for Glioblastoma Response Assessment During Radiation Therapy on a 0.35 T Magnetic Resonance Imaging Linear Accelerator. Int J Radiat Oncol Biol Phys. 2025. PMID: 39993537. doi:10.1016/j.ijrobp.2025.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。